Ignite Creation Date:
2024-05-05 @ 11:07 AM
Last Modification Date:
2024-10-26 @ 9:03 AM
Study NCT ID:
NCT00002349
Status:
COMPLETED
Last Update Posted:
2011-04-14
First Post:
1999-11-02
Brief Title:
A Pilot Study to Compare the Antiviral and Immunologic Effects of Stavudine d4T Versus Placebo in Subjects With Evidence of Recent HIV Infection
Sponsor:
Bristol-Myers Squibb
Organization:
Bristol-Myers Squibb
Study Overview
Official Title:
A Pilot Study to Compare the Antiviral and Immunologic Effects of Stavudine d4T Versus Placebo in Subjects With Evidence of Recent HIV Infection
Status:
COMPLETED
Status Verified Date:
2011-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To compare the antiviral effect of stavudine d4T versus placebo in patients with evidence of recent HIV infection
Also to compare the immunologic effects and effects on quality of life of d4T in these patients
Also to compare the immunologic effects and effects on quality of life of d4T in these patients
Detailed Description:
Patients receive d4T or placebo every 12 hours for 4 weeks after which dose decreases or placebo every 12 hours Treatment continues for at least 48 weeks
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| AI455-029 | None | None | None |